817 top medical experts on Retinoblastoma across 79 countries and 32 U.S. states, including 718 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Retinoblastoma: A malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. The tumor tends to occur in early childhood or infancy and may be present at birth. The majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. Histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. An abnormal pupil reflex (leukokoria); nystagmus, pathologic; strabismus; and visual loss represent common clinical characteristics of this condition. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2104)
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Hereditary Eye Diseases (901), Neuroepithelial Neoplasms (2,390), Retinal Neoplasms (1,969).
  4. Clinical Trials ClinicalTrials.gov : at least 111 including 11 Active, 37 Completed, 33 Recruiting
  5. Synonyms: Retinal Glioblastoma,  Retinal Glioma,  Retinal Neuroblastoma


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Abramson, David Harold   Plastic Surgery   ClinicalTrials.gov Google Publications
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Medical school: New York University School of Medicine (MD, 1988)
    Medicare Accepted
    Disclosed payments in 2021 from 3 biomedical companies, totalling $203.71, including $170.95 from  TELA Bio, Inc.
    Subjects: Retinal Neoplasms; Antineoplastic Agents; Melphalan; Ophthalmic Artery; Vitreous Body
    Categories: Drug Therapy; Administration & Dosage; Pathology; Therapy; Genetics; Diagnosis
    Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. (2011)
    Retinoblastoma. (2015)

  2. Shields, Carol L   Ophthalmology   ClinicalTrials.gov Google Publications
    Ocular Oncology Service, Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medical school: University of Pittsburgh School of Medicine (MD, 1979)
    Medicare Accepted
    Disclosed payments from biomedical company (Carl Zeiss Meditec, Inc.) in 2021 for $13,150
    Subjects: Retinal Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Melphalan; Antineoplastic Agents, Alkylating
    Categories: Drug Therapy; Diagnosis; Administration & Dosage; Therapeutic Use; Pathology; Therapy
    Global Retinoblastoma Presentation and Analysis by National Income Level. (2020)
    Retinoblastoma. (2015)

  3. Dunkel, Ira J   Pediatric Hematology-Oncology   ClinicalTrials.gov Google Publications
    Department of Epidemiology and Biostatistics, MSKCC, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Disclosed payments from biomedical company (AstraZeneca Pharmaceuticals LP) in 2021 for $2,740
    Subjects: Retinal Neoplasms; Antineoplastic Agents; Ophthalmic Artery; Antineoplastic Combined Chemotherapy Protocols; Melphalan
    Categories: Drug Therapy; Administration & Dosage; Diagnosis; Pathology; Surgery; Methods
    Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. (2011)
    Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. (2016)

  4. Brodie, Scott E   Ophthalmology   Google Publications
    Department of Ophthalmology, NYU Langone Health, New York, New York.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medical school: Js Weill Medical College, Cornell University (MD, 1980)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 86/100
    Disclosed payments from biomedical company (Apellis Pharmaceuticals, Inc.) in 2021 for $118.73
    Subjects: Retinal Neoplasms; Antineoplastic Agents; Melphalan; Ophthalmic Artery; Antineoplastic Combined Chemotherapy Protocols
    Categories: Drug Therapy; Administration & Dosage; Drug Effects; Surgery; Therapeutic Use; Methods
    Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. (2011)
    Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. (2016)

  5. Francis, Jasmine H   Ophthalmology   Google Publications
    Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Retinal Neoplasms; Melphalan; Antineoplastic Agents; Vitreous Body; Ophthalmic Artery
    Categories: Drug Therapy; Administration & Dosage; Pathology; Diagnosis; Methods; Drug Effects
    Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. (2016)
    Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. (2014)

  6. Marr, Brian P   Ophthalmology   Google Publications
    Department of Ophthalmology, Columbia University Medical Center, New York, New York, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Retinal Neoplasms; Melphalan; Ophthalmic Artery; Antineoplastic Agents; Vitreous Body
    Categories: Drug Therapy; Administration & Dosage; Methods; Surgery; Drug Effects; Pathology
    Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. (2011)
    Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. (2016)

  7. Shields, Jerry A   Ophthalmology  Google Publications
    Ocular Oncology Service, Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
    Physician  Highly Cited  Highly Published  Case Reports 
    Subjects: Retinal Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents, Alkylating; Melphalan
    Categories: Drug Therapy; Diagnosis; Administration & Dosage; Pathology; Therapeutic Use; Therapy
    Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. (2014)
    Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. (2011)

  8. Gobin, Yves Pierre   Neurological Surgery   Google Publications
    Interventional Neuroradiology, Weill Cornell Medical Center, New York, New York.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medical school: Other (MD, 1988)
    Medicare Accepted
    Subjects: Retinal Neoplasms; Antineoplastic Agents; Ophthalmic Artery; Antineoplastic Combined Chemotherapy Protocols; Melphalan
    Categories: Drug Therapy; Administration & Dosage; Surgery; Pathology; Therapeutic Use; Drug Effects
    Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. (2011)
    Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. (2016)

  9. Jabbour, Pascal M   Neurological Surgery   Google Publications
    Department of Neurological Surgery, Thomas Jefferson University - Center City Campus, Philadelphia, Pennsylvania, USA .
    Physician  Highly Cited  Highly Published  Case Reports 
    Disclosed payments in 2021 from 6 biomedical companies, totalling $22,769.18, including $15,759.18 from  Medtronic, Inc.
    Subjects: Retinal Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Melphalan; Antineoplastic Agents, Alkylating
    Categories: Drug Therapy; Administration & Dosage; Therapeutic Use; Methods; Therapy; Diagnostic Imaging
    Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. (2014)
    Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. (2011)

  10. Wilson, Matthew W   Ophthalmology   Google Publications
    Department of Surgery, St Jude Childrens Research Hospital, Memphis, TN.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medical school: Emory University School of Medicine (MD, 1990)
    Medicare Accepted
    Disclosed payments in 2021 from 2 biomedical companies, totalling $96.25, including $80.84 from  Alcon Vision LLC
    Subjects: Retinal Neoplasms; Antineoplastic Agents; Eye Enucleation; Antineoplastic Combined Chemotherapy Protocols; Carboplatin
    Categories: Drug Therapy; Pathology; Genetics; Therapeutic Use; Adverse Effects; Physiopathology
    Global Retinoblastoma Presentation and Analysis by National Income Level. (2020)
    Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. (2017)

  11. Brennan, Rachel C   Pediatric Hematology-Oncology   ClinicalTrials.gov Google Publications
    Department of Oncology, St. Jude Childrens Research Hospital, Memphis, TN, USA. .
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Retinal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents; Eye Enucleation; Proto-Oncogene Proteins c-mdm2
    Categories: Drug Therapy; Genetics; Pathology; Therapeutic Use; Psychology; Therapy
    Global Retinoblastoma Presentation and Analysis by National Income Level. (2020)
    Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. (2017)

  12. Berry, Jesse L   Ophthalmology   ClinicalTrials.gov Google Publications
    The Vision Center at Childrens Hospital Los Angeles, Los Angeles, California, USA.
    Physician  Highly Cited  Highly Published  Case Reports 
    Relevant US NIH Grant Funding: $915,032 over the last 5 years
    Medicare MIPS (Merit-based Incentive Payment System) rating: 77/100
    Disclosed payments from biomedical company (Alcon Vision LLC) in 2021 for $40.36
    Subjects: Retinal Neoplasms; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases; Aqueous Humor; Salvage Therapy
    Categories: Genetics; Pathology; Drug Therapy; Methods; Therapy; Administration & Dosage
    Global Retinoblastoma Presentation and Analysis by National Income Level. (2020)
    Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. (2013)

  13. Qaddoumi, Ibrahim   Pediatric Hematology-Oncology   ClinicalTrials.gov Google Publications
    St. Jude Childrens Research Hospital, Memphis, TN.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Subjects: Retinal Neoplasms; Carboplatin; Developing Countries; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols
    Categories: Drug Therapy; Therapy; Adverse Effects; Pathology; Physiopathology; Organization & Administration
    Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. (2010)
    Carboplatin-associated ototoxicity in children with retinoblastoma. (2012)

  14. Chantada, Guillermo L   ClinicalTrials.gov Google Publications
    Institut de Recerca Sant Joan de Deu, Barcelona, Spain.
    Scientist  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Subjects: Retinal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Topotecan; Antineoplastic Agents; Melphalan
    Categories: Drug Therapy; Therapy; Genetics; Pathology; Metabolism; Administration & Dosage
    Global Retinoblastoma Presentation and Analysis by National Income Level. (2020)
    Retinoblastoma. (2015)

  15. Jubran, Rima F   Pediatric Hematology-Oncology  ClinicalTrials.gov Google Publications
    Cancer and Blood Disease Institute at Childrens Hospital Los Angeles, Los Angeles, California, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Retinal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Aqueous Humor; Retinoblastoma Binding Proteins; Salvage Therapy
    Categories: Genetics; Drug Therapy; Pathology; Therapy; Methods; Metabolism
    Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. (2013)
    Genomic cfDNA Analysis of Aqueous Humor in Retinoblastoma Predicts Eye Salvage: The Surrogate Tumor Biopsy for Retinoblastoma. (2018)

  16. Skalet, Alison H   Ophthalmology  Google Publications
    Casey Eye Institute, Oregon Health & Science University, Portland. Top Hospital
    Physician  Highly Cited 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 80.3/100
    Subjects: Oncologists; Consensus; Mass Screening; Neuroblastoma; Ophthalmology
    Categories: Diagnosis; Epidemiology; Genetics; Methods; Economics
    Global Retinoblastoma Presentation and Analysis by National Income Level. (2020)
    Retinoblastoma and Neuroblastoma Predisposition and Surveillance. (2017)

  17. Schefler, Amy C   Ophthalmology  Google Publications
    Retina Consultants of Houston, Houston, Texas.
    Physician  Case Reports 
    Disclosed payments in 2021 from 4 biomedical companies, totalling $84.29, including $66.02 from  Regeneron Healthcare Solutions, Inc.
    Subjects: Retinal Neoplasms; Antineoplastic Agents; Laser Coagulation; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols
    Categories: Drug Therapy; Therapeutic Use; Genetics; Pathology; Therapy; Methods
    Global Retinoblastoma Presentation and Analysis by National Income Level. (2020)
    Risk of Extraocular Extension in Eyes With Retinoblastoma Receiving Intravitreous Chemotherapy. (2017)

  18. Kim, Jonathan W   Ophthalmology   ClinicalTrials.gov Google Publications
    The Vision Center at Childrens Hospital Los Angeles, Los Angeles, California, USA.
    Physician  Highly Cited  Highly Published  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72/100
    Subjects: Retinal Neoplasms; Aqueous Humor; Mutation; Retinoblastoma Binding Proteins; Salvage Therapy
    Categories: Pathology; Genetics; Methods; Drug Therapy; Adverse Effects; Therapy
    Global Retinoblastoma Presentation and Analysis by National Income Level. (2020)
    Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. (2013)

  19. Murray, Timothy G   Ophthalmology  Google Publications
    Murray Ocular Oncology and Retina, Miami, Florida, USA.
    Physician  Highly Cited  Highly Published  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 87/100
    Disclosed payments in 2021 from 17 biomedical companies, totalling $20,655.65, including $16,304.25 from  Alcon Vision LLC
    Subjects: Retinal Neoplasms; Melphalan; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Diagnosis; Genetics; Pathology
    Global Retinoblastoma Presentation and Analysis by National Income Level. (2020)
    Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. (2011)

  20. Demirci, Hakan   Ophthalmology  Google Publications
    Department of Ophthalmology, Kellogg Eye Center, University of Michigan, Ann Arbor.
    Physician 
    Medical school: Other (MD, 1993)
    Medicare Accepted
    Disclosed payments from biomedical company (TISSUETECH, INC.) in 2021 for $128.91
    Subjects: Retinal Neoplasms; Epigenesis, Genetic; Melanoma; Photoacoustic Techniques; Polycomb Repressive Complex 2
    Categories: Diagnosis; Pathology; Metabolism; Drug Effects; Economics; Epidemiology
    Global Retinoblastoma Presentation and Analysis by National Income Level. (2020)
    Photoacoustic imaging features of intraocular tumors: Retinoblastoma and uveal melanoma. (2017)

Note:
  1. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);